GeneSegues, Inc. and Collaborators at University of Minnesota Publish New Research Showing Targeted Nanocapsule Delivery of Plasmid DNA for Long Term Treatment of Hemophilia in Mice

MINNEAPOLIS, Minn. – June 8, 2009 – GeneSegues, Inc., a biopharmaceutical company developing and commercializing novel nanocapsule-based drug delivery technology, announced today a publication in the Journal of Clinical Investigation demonstrating that systemic administration of plasmid DNA in liver-targeted, non-viral nanocapsules resulted in complete and long term phenotypic correction of hemophilia A in a mouse model. The work is the result of collaborative studies between GeneSegues and the laboratory of Clifford Steer, M.D., Professor of Medicine, University of Minnesota, and was supported by grants from the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Department of Defense.